Axon Ligands (TM) - alphabetic: [A] [B] [C] [D] [E] [F] [G] [H] [I] [J] [K] [L] [M] [N] [O] [P] [Q] [R] [S] [T] [U] [V] [W] [X] [Y] [Z]

OSI 906 - Linsitinib

CAS 867160-71-2

C26H23ClN5O  MW 421.49

Purity: 99%

Soluble in DMSO

Ordering Information:

Cat. No. Axon 1702    Prime Source Promotion

Qty1: 2 mg (research sample) / €105  $137

Qty2: 5 mg (research sample) / €155  $202

Promotion: 2 x 5 mg @ €230  $300

Qty3: 25 mg (research sample) / €550  $715

Promotion: 2 x 25 mg @ €830  $1080

Qty4: on request contract research synthesis

Send enquiry to: order@axonmedchem.com

or by fax to: +31-50-3600390.

Contact us for our product range and services.

Biological Activity:   Highly potent, orally efficacious and highly selective, dual ATP-competitive tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF-1R) (IC50: 35 nM) and insulin receptor (IR) (IC50: 75 nM).   References: online   MJ Mulvihill et al. Discovery of OSI-906: a selective and orally efficacious dual inhibitor of the IGF-1 receptor and insulin receptor. Fut. Med. Chem. 2009, 1(6), 1153-1171. [online]   CP Carden et al. Phase I study of intermittent dosing of OSI-906, a dual tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR) in patients with advanced solid tumors. J. Clin. Oncol. 2010, 28:15s (suppl; abstr 2530). [online]   V. M. Macaulay et al. Phase I study of OSI-906, dual tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR) in combination with erlotinib (E) in patients with advanced solid tumors. J. Clin. Oncol. 2010, 28:15s (suppl; abstr 3016). [online]     Chemical Name: cis-3-(8-amino-1-(2-phenylquinolin-7-yl)imidazo[1,5-a]pyrazin-3-yl)-1-methylcyclobutanol

OSI 906 - Linsitinib | IGF-1R/IR inhibitor | Axon Medchem | Axon 1702 | OSI906

Axon Ligands ^TM - Research chemicals for biological study. Some high-profile samples could be provided under terms of contract research synthesis.

axonmedchem.com © 2011